USDCHF_2024-07-26 NYK 4hOB News (Price Index)Imagine you always took profits at 10-15 pips.
Easy right?
(most of our trades reach 10 pips profit.
The action of taking profit, no matter how small, would grow the account by default.
Trials
VERU log chart. Wedge within a megaphone and channel.This is a mighty COVID treatment play. It's a coin flip whether it will break up or down out of the blue dashed wedge, but when it does. . . there are many place it can go. Options prices remain elevated even for $10 strikes (around the lower ascending channel). All depends on the Phase III trial data and analysis.
Personally, I bought 1000 shares in the February pullback before the mega rally, sold into strength, and still hold 150. I've been selling $10, $15 and $17.5 strike weekly puts and taking profits at 50% to 75%. I will take any long red candles as an opportunity to sell lower-strike puts.
So my bias is long, but to sell into strength. Caveat emptor.
Easy - LONG Verastem! Chart, Technicals, Cash, Upcoming news....
These guys have a COVID trial that starts June 30th and we have yet to see an 8-k or PR for it.
This is a great time to go long and setup for it....We are looking to finally establish 2.05 support...there are a LOT of shorts to come running home if we do so...
First time we will test with a healthier MACD and CMF on the week....STOCH and RSI look great as well....
not a ton of downside risk - if you want, let go if we break the 200day - but other than that this one is way too easy right now.
ENJOY THE FIRE WORKS <3
ETH.XBT P-Modeling Pt X.1 Shadow Cajuns with Matrix Vectors<<>> Welcome Hyperspace Agent.
In Order to Evolve... Lets take a walk on the wild side of Hyperspace..
Trying some new constructs.
Fractal Shadows with attributed spin/linear networks.
Nestled shadow Inverted Cup.
Mirror Outliers.
Would love to be wrong.
Would love to be right.
Failure is a necessary component of success.
Be fluid like water.
_______________________________________
Ask yourself..
Is the Cat Alive ? or Is the Cat Dead?
Or do we hang in the balance between suspended animation and the ideal that being alive and dead is acceptable?
Laugh now, cry later..
Thoughts to Ponder in these crazy times,
Thanks for Pondering it with me,
Glitch420
$BPTH Posts Positive Phase 2 Trials for Leukemia DrugBio-Path released updated Phase 2 data for its lead candidate prexigebersen, codenamed BP1001, for treating acute myeloid leukemia, or AML, and also divulged a plan of action for taking the compound through clinical development toward registration.
Updated data from the Stage 1 of the Phase 2 study that evaluated the efficacy and safety of prexigebersen in conjunction with the low-dose chemotherapy regimen cytarabine in 17 newly diagnosed AML patients revealed that the proportion of patients showing a response increased from 47 percent when assessed in April 2018 to 65 percent.
Of the patients showing a response, 5, or 29 percent, showed a complete response compared to the benchmarked percentage of 7-13 percent.
AML: A Cancer Of Blood Cells:
AML is a form of blood cancer that develops in the bone marrow, where blood cells originate. It afflicts a group of white blood cells called myeloid cells that develop into mature blood cells such as red blood cells, white blood cells and platelets.
A patient with AML will see rapid accumulation of immature myeloid cells in the blood, resulting in a drop of other blood cell types.
BP1001's Mode Of Action:
Prexigebersen is a neutral-charge, liposome-incorporated antisense drug designed to inhibit protein synthesis of growth factor receptor bound protein 2, or Grb2.
Grb2 has a role to play in cancer cell activation via the RAS pathway.
Inhibition of Grb2 is found to halt cell proliferation and enhance cell killing by chemotherapeutic agents without added toxicity.
A Lucrative Market:
AML accounts for roughly 36 percent of all leukemias, with about 20,000 new cases diagnosed each year, Bio-Path said, citing National Cancer Institute estimates.
A critically unmet need exists for non-toxic therapies for older, fragile AML patients who are unfit or ineligible for high-dose chemotherapy or a stem cell transplant.
What's Next:
Bio-Path said it believes it now has a plan with definable paths to registration.
It plans to amend the Stage 2 prexigebersen + decitabine Phase 2 AML cohort in untreated new patients to add untreated high-risk myelodysplastic syndrome, or MDS, patients.
The company also intends to cancel the Stage 2 prexigebersen + LDAC Phase 2 AML cohort in untreated de novo patients.
It also plans to test a triple combo of prexigebersen + decitabine + venetoclax for untreated AML and high-risk MDS patients in a registration-directed trial to determine if more durable responses and longer survival are observed compared to patients treated with the decitabine + venetoclax combination.
The next major catalyst for Bio-Path will be the fourth-quarter results expected sometime in the next month.
$AITB - AIT Therapeutics Inc - Buy AlertAIT Therapeutics Inc. is a clinical-stage biopharmaceutical company using nitric oxide (NO) to treat serious lung infections and pulmonary hypertension. The Company is currently applying its therapeutic expertise to treat lower respiratory tract infections that are not effectively addressed with current standards of care. AIT Therapeutics is advancing its revolutionary NO respiratory targeted system in clinical trials for the treatment of bronchiolitis and for nontuberculous mycobacteria (NTM). For more information, visit www.AIT-Pharm.com
BKIT bounce play with clinical trials"team appointed to conduct clinical trials of its insomnia products using Blake’s proprietary Zleepax™ formula"
This looks like a typical reversal play after a huge run up. The news from March 2 introduces the team behind the clinical study. There is a huge market for this. Could be a nice reversal play here.
www.otcmarkets.com
Outstanding Shares 31,597,572 a/o May 01, 2017
